Lundbeck's Vyepti Launch In US Disappoints In First Half
But 2020 EBIT Guidance Revised Upwards
The coronavirus pandemic held back sales of Lundbeck’s newest product, Vyepti, in the US during the first half, but the company spent less than expected on SG&A because of COVID-19, and increased investments in marketing infrastructure and restructuring R&D.
You may also be interested in...
Lundbeck wants to rebuild its R&D pipeline of products to treat brain disorders after recent disappointments, a process that could lead to job losses among the research organization, and more emphasis on deal-making.
Lundbeck adapted its launch strategy for its quarterly injectable migraine therapy Vyepti because of the COVID-19 pandemic, becoming more virtual, and payer responses have been encouraging.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.